Search
Influenza A virus A/Singapore/INFIMH-16-0019/2016 (H3N2) live (attenuated) antigen
go.drugbank.com/drugs/DB14696ApprovedWithdrawnUpon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus
Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (UV,formaldehyde inactivated)
go.drugbank.com/drugs/DB14698ApprovedWithdrawnUpon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus
Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB15500ApprovedWithdrawnUpon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus
Influenza B virus B/Singapore/INFTT-16-0610/2016 antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15507ApprovedWithdrawnUpon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus
Influenza B virus B/Iowa/06/2017 antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15508ApprovedWithdrawnUpon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus
Influenza A virus A/Brisbane/02/2018 IVR-190 (H1N1) antigen (UV, formaldehyde inactivated)
go.drugbank.com/drugs/DB15519ApprovedWithdrawnUpon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus
Influenza B virus B/Singapore/INFTT-16-0610/2016 hemagglutinin antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15564ApprovedUpon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus
Exagamglogene autotemcel
go.drugbank.com/drugs/DB15572ApprovedInvestigational[L49231] It is the first CRISPR-based gene editing therapy to be approved in the United States.
Influenza A virus A/Minnesota/41/2019 (H3N2) recombinant hemagglutinin antigen
go.drugbank.com/drugs/DB15701ApprovedWithdrawnUpon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus
Influenza A virus A/Nebraska/14/2019 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB15707ApprovedWithdrawnUpon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus